Sivaramya Kollipara, MD
Dermatology · Dallas, TXNPI 1295179190
Payments from drug & device makers
Across 127 payments — averaging $23.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$936
- Regeneron Healthcare Solutions, Inc.$330
- Johnson & Johnson$244
- Sun Pharmaceutical Industries Inc.$203
- LEO Pharma Inc.$189
- Lilly USA, LLC$181
- plus $932 from 14 others
What the payments were for
- Food & beverage$2,91597%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 41 | $936 |
| Regeneron Healthcare Solutions, Inc. | 14 | $330 |
| Johnson & Johnson | 8 | $244 |
| Sun Pharmaceutical Industries Inc. | 7 | $203 |
| LEO Pharma Inc. | 8 | $189 |
| Lilly USA, LLC | 8 | $181 |
| Sanofi | 6 | $137 |
| Solta Medical, A Division Of Bausch Health US, LLC | 1 | $109 |
| Galderma Laboratories, L.p. | 7 | $107 |
| Novartis | 4 | $100 |
| Almirall LLC | 4 | $99 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $73 |
| Amgen | 4 | $70 |
| Elekta, Inc. | 1 | $56 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Mayne Pharma Commercial LLC | 2 | $37 |
| Incyte Corporation | 2 | $37 |
| Pfizer | 2 | $30 |
| VYNE Pharmaceuticals Inc. | 1 | $20 |
| Stemline Therapeutics Inc. | 1 | $16 |
How this compares
$3,015 in reported general payments places this provider in the 40th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 16 | $571 |
| Triamcinolone Acetonide | 24 | $331 |
| Hydrocortisone | 22 | $207 |
| Ketoconazole | 17 | $180 |
| ValacyclovirValacyclovir Hcl | 13 | $76 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Dallas
- Jennifer CatherDallas$4.9M
- Martin MenterDallas$3.7M
- So Yeon PaekDallas$3.5M
- Ross RaduskyDallas$3.3M
- Joseph MerolaDallas$2.1M
- William AbramovitsDallas$1.8M
- Donald GlassDallas$847K
- Kristel PolderDallas$761K
- Mary HornerDallas$457K
- Gregory PetersonDallas$412K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.